Weight Regain Rapid After Stopping Weight-Loss Jabs, Study Finds

A recent study indicates that individuals who discontinue weight-loss injections regain the weight they lost within two years, outpacing those on other weight management strategies. This research, led by academics at the University of Oxford and published in the BMJ, examined 37 studies involving 9,341 participants and highlighted the challenges associated with long-term weight maintenance after ceasing medication.

The medications in question, known as GLP-1 agonists, were initially developed for diabetes treatment. These drugs work by mimicking the hormone glucagon-like peptide 1 (GLP-1), which helps enhance feelings of fullness. The study revealed that patients lost an average of 8.3 kg during treatment but regained an alarming 4.8 kg within the first year after stopping the injections. On average, participants returned to their original weight within 1.7 years of discontinuing any type of weight-loss medication.

Insights on Weight Regain Patterns

The analysis disclosed that individuals who stopped taking these medications regained weight at a rate of 0.4 kg per month. This rate is four times faster than that observed in participants following behavioural programmes that include dietary and physical activity changes. According to Dr. Sam West from the Nuffield Department of Primary Care Health Sciences, the rapid weight regain is not a failing of the medications themselves but reflects the chronic nature of obesity.

“These medicines are transforming obesity treatment and can achieve significant weight loss,” Dr. West stated. “However, our research shows that people tend to regain weight rapidly after stopping—faster than we see with behavioural programmes.” He cautioned that this underscores the need for a comprehensive approach to long-term weight management.

The findings also indicated that while weight loss medications can improve various health markers, benefits such as reductions in blood pressure and cholesterol levels reverted to baseline within 1.4 years of stopping treatment. This marks the first study to quantify the rate of weight regain and the timeframe for metabolic reversal following discontinuation of these drugs.

Implications for Weight Management Strategies

While medications like Wegovy can be prescribed by the NHS for up to two years, there is no set prescription limit for Mounjaro. Dr. Faye Riley, research communications lead at Diabetes UK, emphasized that although weight-loss drugs can be effective tools, they are not a quick fix. “They need to be prescribed appropriately, with tailored wraparound support alongside them, to ensure people can fully benefit and maintain weight loss for as long as possible when they stop taking the medication,” she noted.

Katharine Jenner, executive director of the Obesity Health Alliance, reinforced that regaining weight after treatment should not be seen as a personal failure. She pointed out that it reflects the realities of living in an environment that often promotes unhealthy food choices. “These drugs can create a window of opportunity to improve the food environment at scale and pace,” Jenner stated, emphasizing the need for broader changes in food marketing and availability to support long-term health benefits.

An NHS spokesperson highlighted that while new treatments are valuable tools for promoting weight loss, they should be complemented with behavioural and lifestyle support. “The NHS continues to implement innovative ways to support people to lose weight safely and sustainably,” the spokesperson said. The NHS plans to expand its digital weight management programme to include an additional 125,000 people annually as part of its ten-year health plan.

As the conversation around obesity and weight management continues to evolve, this study serves as a critical reminder of the complexities involved in long-term weight maintenance and the necessity for comprehensive strategies that go beyond medication alone.